Filing Details
- Accession Number:
- 0001181431-14-002331
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-01-14 13:34:59
- Reporting Period:
- 2014-01-10
- Filing Date:
- 2014-01-14
- Accepted Time:
- 2014-01-14 13:34:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 819050 | Vical Inc | VICL | Biological Products, (No Disgnostic Substances) (2836) | 930948554 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1198238 | B Vijay Samant | 10390 Pacific Center Court San Diego CA 92121 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock $.01 Par Value | Acquisiton | 2014-01-10 | 330,000 | $1.42 | 962,211 | No | 4 | P | Direct | |
| Common Stock $.01 Par Value | Disposition | 2014-01-11 | 2,623 | $1.42 | 959,588 | No | 4 | F | Direct | |
| Common Stock $.01 Par Value | Disposition | 2014-01-11 | 7,398 | $1.42 | 952,190 | No | 4 | F | Direct | |
| Common Stock $.01 Par Value | Disposition | 2014-01-13 | 1,464 | $1.34 | 950,726 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Nonstatutory Stock Option (right to buy) | Acquisiton | 2014-01-10 | 500,000 | $0.00 | 500,000 | $1.42 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,809,000 | 2024-01-09 | No | 4 | A | Direct |
Footnotes
- Shares were acquired pursuant to a restricted stock grant and generally vest one-third on the first anniversary of the grant, with the remainder vesting quarterly over the remaining two years.
- Represents shares withheld for taxes upon the release of restricted stock granted on January 11, 2010.
- Represents shares withheld for taxes upon the release of restricted stock granted on January 11, 2013.
- Represents shares withheld for taxes upon the release of restricted stock granted on January 13, 2012.
- This balance includes 464,450 of unvested restricted stock units.
- The right to exercise the above stock option is tied to performance-based objectives relating to the timing of patient enrollment and positive data release for the Company's Phase 1/2 HSV-2 clinical trial. Mr. Samant's salary remained unchanged at 2013 levels and he received no cash bonus.
Billionaire Hedge Funds
